子宫内膜癌血清肿瘤标志物研究进展

国际肿瘤学杂志››2014,Vol. 41››Issue (5): 364-367.doi:10.3760/cma.j.issn.1673-422X.2014.05.014

子宫内膜癌血清肿瘤标志物研究进展

陈瑞芳,鹿欣

200111上海，复旦大学附属妇产科医院妇瘤科

收稿日期:2013-12-26修回日期:2014-01-17出版日期:2014-05-08发布日期:2014-04-28
通讯作者:鹿欣 E-mail:xinludoc@163.com

Progress on serum tumor biomarkers of endometrial carcinoma

Chen Ruifang, Lu Xin

Department of Female Oncology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China

Received:2013-12-26Revised:2014-01-17Online:2014-05-08Published:2014-04-28
Contact:Lu Xin E-mail:xinludoc@163.com

摘要/Abstract

摘要：血清肿瘤标志物对子宫内膜癌的早期诊断、治疗、术前评估及患者预后预测及肿瘤复发监测等均有重要意义。血清糖类抗原125、人附睾分泌蛋白4是目前较公认的与子宫内膜癌的分期、转移及预后等密切相关的肿瘤标志物。此外，血清微小RNA具有稳定性好、组织特异性高的特点，组学技术能从整体角度分析肿瘤的发生发展，随着这两方面研究的逐步深入，有望找到新的敏感性和特异性均较高的子宫内膜癌血清肿瘤标志物。

关键词:子宫内膜肿瘤,肿瘤标记,生物学,血清

Abstract:Serum tumor biomarkers are significant for the early diagnosis and treatment, preoperative evaluation, prognosis prediction and relapse surveillance of endometrial carcinoma. Recently, serum CA125 and human epididymal secretory protein 4 are widely recognized as closely related with staging, metastasis and prognosis of endometrial cancer. In addition, the serum miRNAs are characterized by their features of high stability and specificity. Omics studies will be helpful for the general assessment of the initiation and progression of endometrial cancer. Insights into these two aspects will facilitate the identifications of new biomarkers with higher sensitivity and specificity for endometrial carcinoma.

Key words:Endometrial neoplasms,Tumor markers, biological,Serum

陈瑞芳,鹿欣. 子宫内膜癌血清肿瘤标志物研究进展[J]. 国际肿瘤学杂志, 2014, 41(5): 364-367.

Chen Ruifang, Lu Xin. Progress on serum tumor biomarkers of endometrial carcinoma[J]. Journal of International Oncology, 2014, 41(5): 364-367.

参考文献

［1］ Chao A, Tang YH, Lai CH, et al. Potential of an agestratified CA125 cutoff value to improve the prognostic classification of patients with endometrial cancer［J］. Gynecol Oncol, 2013, 129(3):500-504. ［2］ Nicklin J, Janda M, Gebski V, et al. The utility of serum CA125 in predicting extrauterine disease in apparent earlystage endometrial cancer［J］. Int J Cancer, 2012, 131(4):885-890. ［3］ Suh DH, Kim HS, Chung HH, et al. Preoperative systemic inflammatory response markers in predicting lymph node metastasis in endometrioid endometrial adenocarcinoma［J］. Eur J Obstet Gynecol Reprod Biol, 2012, 162(2):206-210. ［4］ Yildiz A, Yetimalar H, Kasap B, et al. Preoperative serum CA 125 level in the prediction of the stage of disease in endometrial carcinoma［J］. Eur J Obstet Gynecol Reprod Biol, 2013, 164(2):191-195. ［5］ Yu B, Xu PZ, Wang QW, et al. Clinical value of tumor specific growth factor(TSGF) and carbohydrate antigen125(CA125) in carcinoma of the endometrium［J］. J Int Med Res, 2009, 37(3):878-883. ［6］ MutzDehbalaie I, Eqle D, Fessler S, et al. HE4 is an independent prognostic marker in endometrial cancer patients［J］. Gynecol Oncol, 2012, 126(2):186-191. ［7］ Moore RG, Brown AK, Miller MC, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus［J］. Gynecol Oncol, 2008, 110(2):196-201. ［8］ Angioli R, Plotti F, Capriglione S, et al. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study［J］. Tumour Biol, 2013, 34(1):571-576. ［9］ Saarelainen SK, Peltonen N, Lehtimki T, et al. Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma［J］. Am J Obstet Gynecol, 2013, 209(2):142.e1-6. ［10］ Kalogera E, Scholler N, Powless C, et al. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer［J］. Gynecol Oncol, 2012, 124(2):270-275. ［11］ Wang LJ, Zhou H, Lu HW, et al. Prognostic value of preoperative serum high sensitivity Creactive protein in patients with endometrial cancer［J］. Zhonghua Yi Xue Za Zhi, 2011, 91(41):2927-2930. ［12］ Li S, Shin HJ, Ding EL, et al. Adiponectin levels and risk of type 2 diabetes: a systematic review and metaanalysis［J］. JAMA, 2009, 302(2):179-188. ［13］ Karahanoglu E, Adanir I, Boyraz G, et al. Preoperative serum leptin levels in patients with endometrial cancer and its correlation with prognostic variables［J］. Eur J Gynaecol Oncol, 2012, 33(3):278-280. ［14］颜春晓, 盛修贵.子宫内膜癌血管生成相关因子研究进展［J］. 国际肿瘤学杂志, 2012, 39(3):230-233. ［15］ Dobrzycka B, Terlikowski SJ, Kowalczuk O, et al. Serum levels of VEGF and VEGFC in patients with endometrial cancer［J］. Eur Cytokine Netw, 2011, 22(1):45-51. ［16］ Coenegrachts L, Schrauwen S, Van Bree R, et al. Increased expression of placental growth factor in highgrade endometrial carcinoma［J］. Oncol Rep, 2013, 29(2):413-418. ［17］ Dobrzycka B, MackowiakMatejczyk B, Kinalski M, et al. Pretreatment serum levels of bFGF and VEGF and its clinical significance in endometrial carcinoma［J］. Gynecol Oncol, 2013, 128(3):454-460. ［18］ Fan JT, Si XH, Liao Y, et al. The diagnostic and prognostic value of serum YKL40 in endometrial cancer［J］. Arch Gynecol Obstet, 2013, 287(1):111-115. ［19］ Diefenbach CS, Shah Z, Iasonos A, et al. Preoperative serum YKL40 is a marker for detection and prognosis of endometrial cancer［J］. Gynecol Oncol, 2007, 104(2):435-442. ［20］梁静, 马本红, 张贵宇. 微RNA与子宫内膜癌［J］. 国际肿瘤学杂志, 2011, 38(11):854858. ［21］ Tan ZQ, Liu FX, Tang HL, et al. Expression and its clinical significance of hsamiR155 in serum of endometrial cancer［J］. Zhonghua Fu Chan Ke Za Zhi, 2010, 45(10):772-774. ［22］ Lee JW, Park YA, Choi JJ, et al. The expression of the miRNA200 family in endometrial carcinoma［J］. Gynecol Oncol, 2011, 120(1):56-62. ［23］ Van Gorp T, Cadron I, Vergote I. The utility of proteomics in gynecologic cancers［J］. Curr Opin Obstet Gynecol, 2011, 23(1):3-7. ［24］ DeSouza LV, Krakovska O, Darfler MM, et al. mTRAQbased quantification of potential endometrial carcinoma biomarkers from archived formalinfixed paraffinembedded tissues［J］. Proteomics, 2010, 10(17):3108-3116. ［25］ Liang H, Cheung LW, Li J, et al. Wholeexome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer［J］. Genome Res, 2012, 22(11): 2120-2129. ［26］ Altme S, Esteban FJ, StavreusEvers A, et al. Guidelines for the design, analysis and interpretation of ′omics′ data: focus on human endometrium［J］. Hum Reprod Update, 2014, 20(1):12-28. ［27］蔡彦卿. 差异蛋白质组学技术鉴定的子宫内膜癌标记蛋白［J］. 国际肿瘤学杂志, 2008, 35(6):461-463.

[1]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[2]	李丹, 李睿尧, 李膺函, 于秀艳, 吴雪峰.血清miR-19b、miR-744-5p水平在非小细胞肺癌诊断中的临床价值[J]. 国际肿瘤学杂志, 2024, 51(2): 83-88.
[3]	凡梦思, 陆雅萍, 闫莉.子宫内膜癌前哨淋巴结假阴性患者的临床病理特征分析[J]. 国际肿瘤学杂志, 2023, 50(5): 274-279.
[4]	刘博翰, 黄俊星.溶质载体SLC7A5及SLC7A11基因在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 280-284.
[5]	杨洪娟, 孙云川, 何新颖, 毕建强, 肖丽.子宫内膜中肾样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(4): 255-256.
[6]	吕璐, 孙鹏飞, 崔腾璐.子宫内膜癌颈部淋巴结转移综合治疗1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(11): 701-704.
[7]	金明, 甄书青, 王彦巧, 申红霞, 张爱民, 回丽妹.丙泊酚对前列腺癌DU145细胞恶性生物学行为的影响及其机制[J]. 国际肿瘤学杂志, 2022, 49(8): 453-458.
[8]	李宁, 张玢琪.免疫检查点抑制剂在子宫内膜癌中的应用[J]. 国际肿瘤学杂志, 2022, 49(2): 125-128.
[9]	鲁历历, 孙鹏飞, 叶斌强.放化疗联合盐酸安罗替尼治疗复发性子宫内膜癌1例[J]. 国际肿瘤学杂志, 2022, 49(12): 766-768.
[10]	徐秋月, 马咸梅, 岳琦.基于分子分型的子宫内膜癌免疫治疗[J]. 国际肿瘤学杂志, 2022, 49(11): 700-704.
[11]	邓波儿, 孔为民.子宫内膜癌的表观遗传学研究进展[J]. 国际肿瘤学杂志, 2021, 48(3): 184-188.
[12]	黎立喜, 马飞.乳腺癌筛查和早期诊断的血液生物学标志物[J]. 国际肿瘤学杂志, 2021, 48(2): 109-112.
[13]	詹晓芬, 翁雪芬, 杨时煌, 许镒洧, 彭裕辉, 郭竑.基于血清蛋白质组分析技术鉴定鼻咽癌ENO1自身抗体诊断分子标志物[J]. 国际肿瘤学杂志, 2020, 47(9): 513-517.
[14]	黄于庭, 汪超.盐酸小檗碱联合表柔比星、顺铂对晚期子宫内膜癌的抗肿瘤效果[J]. 国际肿瘤学杂志, 2020, 47(9): 530-534.
[15]	张敏, 周丽娜, 徐姗姗, 陈骏.肿瘤免疫治疗相关预测生物标志物研究进展[J]. 国际肿瘤学杂志, 2020, 47(8): 487-491.